Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 95

1.

Allogeneic stem cell transplantation for patients with relapsed or refractory T-cell lymphoma: efficacy of lymphoma-directed conditioning against advanced disease.

Wulf G, Hasenkamp J, Jung W, Wilhelm C, Held G, Nickelsen M, Leha A, Pfreundschuh M, Schmitz N, Trümper L, Glass B.

Bone Marrow Transplant. 2019 Jun;54(6):877-884. doi: 10.1038/s41409-018-0360-9. Epub 2018 Nov 9.

PMID:
30413811
2.

Allogeneic stem cell transplantation after a fludarabine/busulfan-based reduced-intensity conditioning in patients with myelodysplastic syndrome or secondary acute myeloid leukemia.

Kröger N, Bornhäuser M, Ehninger G, Schwerdtfeger R, Biersack H, Sayer HG, Wandt H, Schäfer-Eckardt K, Beyer J, Kiehl M, Zander AR; German Cooperative Transplant Study Group.

Ann Hematol. 2003 Jun;82(6):336-42. Epub 2003 May 1.

PMID:
12728337
4.

Fludarabine-melphalan as a preparative regimen for reduced-intensity conditioning allogeneic stem cell transplantation in relapsed and refractory Hodgkin's lymphoma: the updated M.D. Anderson Cancer Center experience.

Anderlini P, Saliba R, Acholonu S, Giralt SA, Andersson B, Ueno NT, Hosing C, Khouri IF, Couriel D, de Lima M, Qazilbash MH, Pro B, Romaguera J, Fayad L, Hagemeister F, Younes A, Munsell MF, Champlin RE.

Haematologica. 2008 Feb;93(2):257-64. doi: 10.3324/haematol.11828. Epub 2008 Jan 26.

5.

Allogeneic transplantation following a reduced-intensity conditioning regimen in relapsed/refractory peripheral T-cell lymphomas: long-term remissions and response to donor lymphocyte infusions support the role of a graft-versus-lymphoma effect.

Dodero A, Spina F, Narni F, Patriarca F, Cavattoni I, Benedetti F, Ciceri F, Baronciani D, Scimè R, Pogliani E, Rambaldi A, Bonifazi F, Dalto S, Bruno B, Corradini P.

Leukemia. 2012 Mar;26(3):520-6. doi: 10.1038/leu.2011.240. Epub 2011 Sep 9.

6.

Extracorporeal photophoresis: an evidence-based analysis.

Medical Advisory Secretariat.

Ont Health Technol Assess Ser. 2006;6(6):1-82. Epub 2006 Mar 1.

8.

Allogeneic stem cell transplantation using lymphoablative rather than myeloablative conditioning regimen for relapsed or refractory lymphomas.

Yoon JH, Jeon YW, Lee SE, Cho BS, Eom KS, Kim YJ, Lee S, Kim HJ, Min CK, Lee JW, Min WS, Cho SG.

Hematol Oncol. 2017 Mar;35(1):17-24. doi: 10.1002/hon.2201. Epub 2015 Mar 18.

PMID:
25782369
9.

Bone marrow versus peripheral blood allogeneic haematopoietic stem cell transplantation for haematological malignancies in adults.

Holtick U, Albrecht M, Chemnitz JM, Theurich S, Skoetz N, Scheid C, von Bergwelt-Baildon M.

Cochrane Database Syst Rev. 2014 Apr 20;(4):CD010189. doi: 10.1002/14651858.CD010189.pub2. Review.

PMID:
24748537
10.

A fludarabine-based dose-reduced conditioning regimen followed by allogeneic stem cell transplantation from related or unrelated donors in patients with myelodysplastic syndrome.

Kröger N, Schetelig J, Zabelina T, Krüger W, Renges H, Stute N, Schrum J, Kabisch H, Siegert W, Zander AR.

Bone Marrow Transplant. 2001 Oct;28(7):643-7.

11.

[Salvage Trerapy for Patients with Relapsed and Refractory Lymphoma by Allogeneic Hematopoietic Stem Cell Transplantation].

Yin Y, Qiu ZX, Li Y, Xu WL, Sun YH, Liu W, Wang WS, Wang MJ, Wang LH, Dong YJ, Ou JP, Cen XN, Ren HY.

Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2017 Apr;25(2):418-425. doi: 10.7534/j.issn.1009-2137.2017.02.020. Chinese.

PMID:
28446286
12.

Risk factors for outcome in refractory acute myeloid leukemia patients treated with a combination of fludarabine, cytarabine, and amsacrine followed by a reduced-intensity conditioning and allogeneic stem cell transplantation.

Pfrepper C, Klink A, Behre G, Schenk T, Franke GN, Jentzsch M, Schwind S, Al-Ali HK, Hochhaus A, Niederwieser D, Sayer HG.

J Cancer Res Clin Oncol. 2016 Jan;142(1):317-24. doi: 10.1007/s00432-015-2050-y. Epub 2015 Sep 30.

PMID:
26424692
13.

Low-dose total body irradiation, fludarabine, and antithymocyte globulin conditioning for nonmyeloablative allogeneic transplantation.

Grosskreutz C, Ross V, Scigliano E, Fruchtman S, Isola L.

Biol Blood Marrow Transplant. 2003 Jul;9(7):453-9.

14.

Outcomes of myeloablative peripheral blood stem cell transplantation for non-complete remission patients with relapsed/refractory peripheral T cell lymphomas.

Gu Z, Wang L, Wang Q, Li H, Bo J, Wang S, Zhao Y, Li F, Gao C, Liu D, Huang W.

Ann Hematol. 2019 May;98(5):1237-1247. doi: 10.1007/s00277-018-3559-3. Epub 2018 Dec 11.

PMID:
30539277
15.

Durable clinical, cytogenetic, and molecular remissions after allogeneic hematopoietic cell transplantation for refractory Sezary syndrome and mycosis fungoides.

Molina A, Zain J, Arber DA, Angelopolou M, O'Donnell M, Murata-Collins J, Forman SJ, Nademanee A.

J Clin Oncol. 2005 Sep 1;23(25):6163-71.

PMID:
16135483
16.

Sequential Conditioning with Thiotepa in T Cell- Replete Hematopoietic Stem Cell Transplantation for the Treatment of Refractory Hematologic Malignancies: Comparison with Matched Related, Haplo-Mismatched, and Unrelated Donors.

Duléry R, Ménard AL, Chantepie S, El-Cheikh J, François S, Delage J, Giannotti F, Ruggeri A, Brissot E, Battipaglia G, Malard F, Belhocine R, Sestili S, Vekhoff A, Delhommeau F, Reman O, Legrand O, Labopin M, Rubio MT, Mohty M.

Biol Blood Marrow Transplant. 2018 May;24(5):1013-1021. doi: 10.1016/j.bbmt.2018.01.005. Epub 2018 Jan 11.

17.

Allogeneic stem cell transplantation with BEAM and alemtuzumab conditioning immediately after remission induction has curative potential in advanced T-cell non-Hodgkin's lymphoma.

Czajczynska A, Günther A, Repp R, Humpe A, Schub N, Raff T, Nickelsen M, Schrauder A, Schrappe M, Kneba M, Gramatzki M.

Biol Blood Marrow Transplant. 2013 Nov;19(11):1632-7. doi: 10.1016/j.bbmt.2013.07.003. Epub 2013 Jul 11.

18.

Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases.

Slavin S, Nagler A, Naparstek E, Kapelushnik Y, Aker M, Cividalli G, Varadi G, Kirschbaum M, Ackerstein A, Samuel S, Amar A, Brautbar C, Ben-Tal O, Eldor A, Or R.

Blood. 1998 Feb 1;91(3):756-63.

PMID:
9446633
19.

Reliable engraftment, low toxicity, and durable remissions following allogeneic blood stem cell transplantation with minimal conditioning.

Kobbe G, Schneider P, Aivado M, Zohren F, Schubert D, Fenk R, Neumann F, Kronenwett R, Pape H, Rong A, Royer-Pokora B, Hildebrandt B, Germing U, Gattermann N, Heyll A, Haas R.

Exp Hematol. 2002 Nov;30(11):1346-53.

PMID:
12423689
20.

Successful treatment of relapsed T-cell non-Hodgkin's lymphoma with allogeneic peripheral blood stem cell transplantation with double conditioning.

Oji Y, Oka Y, Tatekawa T, Soma T, Matsunashi T, Yamagami T, Tsuboi A, Tamaki H, Kim EH, Sugiyama H, Ogawa H.

Int J Hematol. 1999 Jun;69(4):263-7.

PMID:
10407585

Supplemental Content

Support Center